Thirteen years to get from b to a:one of the neglected isoforms of IL-37 enters the stage  

作　　者：Steven X.Cho Ina Rudloff Andrew M.Ellisdon Claudia A.Nold-Petry Marcel F.Nold 

机构地区：[1]Ritchie Centre,Hudson Institute of Medical Research,Melbourne,VIC,Australia [2]Department of Pediatrics,Monash University,Melbourne,VIC,Australia [3]Cancer Program,Biomedicine Discovery Institute,Monash University,Melbourne,VIC,Australia [4]Monash Newborn,Monash Children’s Hospital,Melbourne,VIC,Australia

出　　处：《Cellular & Molecular Immunology》2024年第2期201-202,共2页中国免疫学杂志（英文版）

摘　　要：Interleukin(IL)-37 is one of the few anti-inflammatory members of the predominantly pro-inflammatory IL-1 cytokine family.IL-37 possesses alarmin-like properties[1]and exerts its activities via intracellular[2]as well as cell surface receptor-dependent mechanisms,and the latter involves IL-1R8 and IL-18Rα[3].Because of its powerful and broad-spectrum“peacemaking”[4]functions,considerable efforts have been invested in developing IL-37-based anti-inflammatory therapeutics[5,6].

关 键 词：INTERLEUKIN NEGLECTED CYTOKINE 

分 类 号：R392[医药卫生—免疫学]